Research graph
References from Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414). Local targets link to admitted publications; unresolved targets remain external evidence.
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
10.1093/annonc/mdy275 · 2018 · External reference
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
10.1093/annonc/mdy474 · 2019 · External reference
New windows open for immunotherapy in lung cancer
10.1038/d41586-018-05312-9 · 2018 · External reference
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial [published correction appears in Lancet. 2017;389:e5]
10.1016/s0140-6736(16)32517-x · 2017 · External reference
Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer
10.1016/j.jtho.2018.04.039 · 2018 · External reference
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
10.1093/annonc/mdx096 · 2017 · External reference
Unresolved reference
External reference
Unresolved reference
2019 · External reference
The good, the bad and the unknown of CD38 in the metabolic microenvironment and immune cell functionality of solid tumors
10.3390/cells9010052 · 2020 · External reference
CD38 knockout suppresses tumorigenesis in mice and clonogenic growth of human lung cancer cells
10.1093/carcin/bgx137 · 2018 · External reference
CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade
10.1158/2159-8290.cd-17-1033 · 2018 · External reference
PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance [published correction appears in Nat Immunol. 2019;20:1555]
10.1038/s41590-019-0441-y · 2019 · External reference
Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
10.1182/blood-2015-12-687749 · 2016 · External reference
Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications
10.1200/jco.19.00189 · 2019 · External reference
Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer
10.1200/jco.2018.79.0006 · 2018 · External reference
